Advertisement

Journal of Gender, Culture and Health

, Volume 4, Issue 4, pp 293–305 | Cite as

Gender, Ethnic, and Geographic Variations in Psychotropic Drug Use Among Children Enrolled in Medicaid

  • Michael H. Fox
  • Carly Hayden Foster
Article

Abstract

This study examines variations in psychotropic drug use among children enrolled in Medicaid during 1995 in two midwestern states. A dataset was created from Kansas Medicaid prescription reimbursement claims and enrollment files that included age, gender, ethnicity, diagnoses, and drugs prescribed for each of the 5,574 children under age 20 years who received at least one psychotropic drug prescription in 1995. A similar database composed of information on 41,031 children from another midwestern state was used for comparisons between the two states. We found that boys were far more likely to receive psychotropic drug prescriptions than were girls. The overall ratio of male to female psychotropic drug users is highest among younger children and nearly equal among older adolescents. While African-American and Hispanic children represented 23% and 12%, respectively, of all children enrolled in Medicaid, they accounted for only 12% and 3.5% of psychotropic drug users, respectively. The striking differences in psychotropic drug use found suggest that patient gender may influence diagnosis and treatment in a way that physiological differences alone cannot account for. Ethnic disparities found here indicate possible access problems or underdiagnoses for minority children. Future efforts to improve the mental health of young people must include attempts to identify the causes of these disparities.

psychotropic children gender Medicaid 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. Boyle, C. A., Decoufle, P., & Yeargin-Allsopp, M. (1994). Prevalence and health impact of developmental disabilities in US children. Pediatrics, 93(3), 399–403.Google Scholar
  2. Byrne, J. M., Bawden, H. N., DeWolfe, N. A., & Beattie, T. L. (1998). Clinical assessment of psychopharmacological treatment of preschoolers with ADHD. Journal of Clinical and Experimental Neuropsychology, 20(5), 613–627.Google Scholar
  3. Center for Mental Health Services. Children and Adolescent's Mental Health (1997). Caring for every child's mental health: Communities together campaign. Washington, DC: U.S. Department of Health and Human Services.Google Scholar
  4. Chase, M. (1999, May 17). Studies of Ritalin's role in drug abuse produce contradictory findings. Wall Street Journal, p. B1.Google Scholar
  5. Cyr, M., & Brown, C. S. (1998). Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. Drugs, 56(2), 215–223.Google Scholar
  6. Gitlin, M.J. (1996). The psychotherapist's guide to psychopharmacology. New York: Free Press.Google Scholar
  7. Greenhill, L. L. (1998). The use of psychotropic medication in preschoolers: Indications, safety and efficacy. Canadian Journal of Psychiatry, 43, 576–581.Google Scholar
  8. Jensen, P. S. (1998). Ethical and pragmatic issues in the use of psychotropic agents in young children. Canadian Journal of Psychiatry, 43, 585–588.Google Scholar
  9. Jensen, P. S., Vitiello, B., Leonard, H., & Laughren, T. P. (1994). Design and methodology issues for clinical treatment trials in children and adolescents. Child and adolescent psychopharmacology: Expanding the research base. Psychopharmacology Bulletin, 30, 3–8.Google Scholar
  10. Padget, D. K., Patrick, C., Burns, B. J., & Schlesinger, H. J. (1994). Ethnicity and the use of outpatient mental health services in a national insured population. American Journal of Public Health, 84(2), 222–226.Google Scholar
  11. Riggs, P. D., Leon, S. L., Sikulick, S. K., & Pottle, L. C. (1998). An open trial of Burpropion for ADHD in adolescents with substance use disorders and conduct disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 12.Google Scholar
  12. Safer, D. J. (1994, October). Patterns of psychotropic medication prescribed by child psychiatrists in the 1990s. Abstract presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry.Google Scholar
  13. Shapiro, S. (1987). An experiment to change detection and management of mental morbidity in primary care. Medical Care, 25(4), 327–339.Google Scholar
  14. Vitiello, B. (1998). Pediatric pharmacology and the interaction between drugs and the developing brain. Canadian Journal of Psychiatry, 43, 582–584.Google Scholar
  15. Wolraich, M. L., Lindgren, S., Stromquist, A., Milich, R., Davis, C., & Watson, D. (1990). Stimulant medication use by primary care physicians in the treatment of attention deficit hyperactivity disorder. Pediatrics, 86(1), 95–101.Google Scholar
  16. Zito, J. M., Safer, D. J., dosReis, S., & Riddle, M. A. (1998). Racial disparities in psychotropic medications prescribed for youths with Medicaid insurance in Maryland. Journal of the American Academy of Child and Adolescent Psychiatry, 37(2), 179–184.Google Scholar
  17. Zito, J. M., Safer, D. S., Riddle, M. A., Johnson, R. E., Speedie, S. M., and Fox, M. (1998). Prevalence variations in psychotropic treatment of children. Journal of Child and Adolescent Psychopharmacology, 8(2), 99–105.Google Scholar

Copyright information

© Plenum Publishing Corporation 1999

Authors and Affiliations

  • Michael H. Fox
    • 1
  • Carly Hayden Foster
    • 1
  1. 1.Department of Health Policy and ManagementUniversity of KansasLawrence

Personalised recommendations